Predict your next investment

HEALTHCARE | Biotechnology
diadembio.com

See what CB Insights has to offer

Founded Year

2019

Stage

Convertible Note | Alive

About Diadem Biotherapeutics

Didadem Biotherapeutics develops first-in-class engineered exosomes to treat chronic inflammatory and auto-immune conditions.

Diadem Biotherapeutics Headquarter Location

479 Jessie St

San Francisco, California, 94103,

United States

Latest Diadem Biotherapeutics News

Diadem Biotherapeutics Awarded the First Amgen Golden Ticket

Sep 15, 2021

Diadem Biotherapeutics Awarded the First Amgen Golden Ticket Diadem Biotherapeutics Awarded the First Amgen Golden Ticket Will receive one year of lab space at BioLabs LA at The Lundquist Institute and additional facility benefits and connections to Amgen's scientific leaders. 09.15.21 Amgen and The Lundquist Institute have awarded Diadem Biotherapeutics, Inc. with the first Amgen Golden Ticket in Southern California. Diadem will receive one year of lab space at BioLabs LA at The Lundquist Institute (TLI) as well as additional facility benefits and connections to Amgen's scientific and business leaders. The 2021 Amgen Golden Ticket winner was chosen by an internal team of Amgen scientific leaders. Five finalists pitched their business plans before Amgen's internal committee that evaluated the strength and novelty of their scientific rationale, subject matter expertise and business plan viability. This is the first of three Amgen Golden Tickets to be awarded over the next three years to help accelerate life science start-ups in Southern California. "Amgen's partnership with BioLabs LA at The Lundquist Institute (TLI) recognizes the rapid growth of bioscience innovation in the Los Angeles area and aligns with our aspiration to bring breakthrough therapies for patients. We are enthusiastic about the exosome technology that is being advanced by Diadem Biosciences, and look forward to engaging with the team as they advance novel immunotherapies to treat serious illness" – Philip Tagari, Ph.D., vice president of Therapeutic Discovery at Amgen   "We are honored to have our approach to therapeutic signaling endorsed by an expert judging panel of Amgen's leading scientists. With the extensive resources at BioLabs LA and access to Amgen expertise we can accelerate the development of a new class of therapeutics that has the potential to enhance patient-care outcomes across a range of diseases. That BioLabs LA is now at full capacity speaks to the ambition of biotech startups in Los Angeles, and the fertile ground of this ecosystem," said Mickey Pentecost, Ph.D., co-founder and chief executive officer, Diadem Biotherapeutics, Inc. 09.15.21 09.13.21 09.10.21 09.07.21 09.02.21 08.30.21 08.27.21 08.26.21 08.25.21 08.18.21 08.13.21 08.12.21 08.11.21 08.11.21 08.10.21

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Diadem Biotherapeutics Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Diadem Biotherapeutics Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.